Last reviewed · How we verify
AZD3293
At a glance
| Generic name | AZD3293 |
|---|---|
| Also known as | beta secretase inhibitor, Beta secretase inhibitor |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia (PHASE3)
- An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (PHASE2, PHASE3)
- A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (PHASE3)
- A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants (PHASE1)
- A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (PHASE1)
- A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants (PHASE1)
- A Study of Lanabecestat (LY3314814) in Healthy Participants (PHASE1)
- A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD3293 CI brief — competitive landscape report
- AZD3293 updates RSS · CI watch RSS
- AstraZeneca portfolio CI